 CAMBRIDGE, Mass., Aug. 17, 2021 GLOBE NEWSWIRE -- TCR2 Therapeutics Inc. Nasdaq: TCRR, a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that their interim update on the Phase 12 clinical trial of gavo-cel will be featured in the official Press Programme at the European Society for Medical Oncology ESMO. Additionally, due to TCR2 opting to not present its accepted featured poster presentation on September 8, 2021 at the World Conference on Lung Cancer WCLC, the Company was notified by the WCLC of their decision to withdraw its abstract titled Phase 1 Trial of Gavocabtagene Autoleucel gavo-cel, TC-210 In Refractory Mesothelin-Expressing Solid Tumors. 